By Cecilia Butini

BioNTech SE on Monday posted revenue and net profit for the first quarter which more than tripled on-year, and backed its outlook for 2022, including on revenues from its Covid-19 vaccine.

The German pharmaceutical company--which has developed, together with Pfizer Inc., one of the most widely sold vaccines against Covid-19--posted net profit of 3.70 billion euros ($3.90 billion) for the quarter. It had made EUR1.13 billion in net profit in the comparable quarter the previous year.

Earnings per share also soared in the quarter, reaching EUR14.24 from EUR4.39 in the same quarter of 2021. Revenue rose to EUR6.37 billion from EUR2.05 billion the year prior, BioNtech said.

The company backed its outlook for 2022, which includes estimated sales of its Covid-19 vaccine in the range of EUR13 billion and EUR17 billion, it said.

As of the first quarter, BioNTech and its partner Pfizer have invoiced about 750 million vaccine doses, and have signed orders for about 2.4 billion doses as of the end of April, the company said. According to BioNTech, it and Pfizer will deliver more than two billion vaccine doses to low- and middle-income countries by year-end.

Chief Executive Ugur Sahin said that the company is well-positioned to achieve multiple product launches in the coming years, which would fuel significant long-term growth.


Write to Cecilia Butini at cecilia.butini@wsj.com


(END) Dow Jones Newswires

05-09-22 0641ET